REGENXBIO To Host Conference Call on November 4 to Discuss Third Quarter 2020 Financial Results and Recent Operational Highlights

Rhea-AI Summary

REGENXBIO (Nasdaq: RGNX) will host a conference call on November 4, 2020, at 4:30 p.m. ET to discuss its financial results for the third quarter ended September 30, 2020. The company aims to enhance lives through gene therapy using its proprietary NAV Technology Platform. Investors can access the call by phone or through a webcast available for 30 days. The platform includes over 100 novel AAV vectors, showcasing the company's commitment to developing a diverse pipeline of gene therapy candidates.

Positive

• Company plans to discuss financial results for Q3 2020, providing transparency to investors.

Negative

• None.

ROCKVILLE, Md., Oct. 28, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV^® Technology Platform, today announced that it will host a conference call on Wednesday, November 4, 2020, at 4:30 p.m. ET to discuss its financial results for the quarter ended September 30, 2020, and recent operational highlights.

To access the live call by phone, dial (855) 422-8964 (domestic) or (210) 229-8819 (international) and enter the passcode 4107819. To access a live or recorded webcast of the call, please visit the Investors section of the REGENXBIO website at www.regenxbio.com. The recorded webcast will be available for approximately 30 days following the call.

About REGENXBIO Inc.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.

 

 

Contacts:

 

Tricia Truehart
Investor Relations and Corporate Communications
347-926-7709

Investors:
Eleanor Barisser, 212-600-1902
eleanor@argotpartners.com

Media:
David Rosen, 212-600-1902
david.rosen@argotpartners.com

View original content:http://www.prnewswire.com/news-releases/regenxbio-to-host-conference-call-on-november-4-to-discuss-third-quarter-2020-financial-results-and-recent-operational-highlights-301162109.html

SOURCE REGENXBIO Inc.

FAQ

What is the date of REGENXBIO's Q3 2020 earnings call?

The Q3 2020 earnings call is scheduled for November 4, 2020.

How can I access the REGENXBIO conference call?

You can access the call by phone at (855) 422-8964 domestically or (210) 229-8819 internationally, or through a live or recorded webcast on their website.

What financial results will REGENXBIO announce?

REGENXBIO will announce its financial results for the quarter ended September 30, 2020.

What is REGENXBIO's NAV Technology Platform?

The NAV Technology Platform is a proprietary gene delivery system consisting of over 100 novel AAV vectors.

How long will the recorded webcast of the call be available?

The recorded webcast will be available for approximately 30 days following the call.